Stock Traders Buy Large Volume of Cambrex Call Options (NYSE:CBM)

Cambrex Co. (NYSE:CBM) was the target of unusually large options trading activity on Thursday. Investors purchased 669 call options on the company. This is an increase of approximately 1,034% compared to the typical daily volume of 59 call options.

Shares of Cambrex stock opened at $59.77 on Friday. The firm has a market capitalization of $2.02 billion, a PE ratio of 21.58, a price-to-earnings-growth ratio of 4.70 and a beta of 2.36. The company has a debt-to-equity ratio of 0.78, a current ratio of 2.44 and a quick ratio of 1.77. The company’s fifty day moving average price is $47.57 and its two-hundred day moving average price is $42.62. Cambrex has a 52-week low of $33.80 and a 52-week high of $69.43.

Institutional investors have recently made changes to their positions in the business. Waddell & Reed Financial Inc. bought a new stake in shares of Cambrex in the 2nd quarter valued at about $6,945,000. Nuveen Asset Management LLC increased its stake in shares of Cambrex by 349.9% in the 2nd quarter. Nuveen Asset Management LLC now owns 180,545 shares of the biotechnology company’s stock valued at $8,451,000 after acquiring an additional 140,418 shares during the last quarter. Marshall Wace LLP increased its stake in shares of Cambrex by 4,787.6% in the 2nd quarter. Marshall Wace LLP now owns 38,123 shares of the biotechnology company’s stock valued at $1,785,000 after acquiring an additional 37,343 shares during the last quarter. Morgan Stanley increased its stake in shares of Cambrex by 4.8% in the 2nd quarter. Morgan Stanley now owns 164,300 shares of the biotechnology company’s stock valued at $7,691,000 after acquiring an additional 7,452 shares during the last quarter. Finally, Bank of America Corp DE increased its stake in shares of Cambrex by 4.1% in the 2nd quarter. Bank of America Corp DE now owns 236,210 shares of the biotechnology company’s stock valued at $11,057,000 after acquiring an additional 9,381 shares during the last quarter.

CBM has been the topic of a number of research reports. Robert W. Baird lowered shares of Cambrex from an “outperform” rating to a “neutral” rating and set a $44.00 target price on the stock. in a research report on Friday, May 3rd. They noted that the move was a valuation call. First Analysis lowered shares of Cambrex from a “strong-buy” rating to an “outperform” rating and boosted their target price for the stock from $45.00 to $55.00 in a research report on Tuesday, May 7th. Zacks Investment Research lowered shares of Cambrex from a “buy” rating to a “hold” rating in a research report on Wednesday, July 24th. William Blair lowered shares of Cambrex from an “outperform” rating to a “market perform” rating and set a $60.00 target price on the stock. in a research report on Wednesday, August 7th. Finally, ValuEngine raised shares of Cambrex from a “buy” rating to a “strong-buy” rating in a research report on Thursday, August 8th. Five equities research analysts have rated the stock with a hold rating, one has assigned a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Hold” and a consensus price target of $52.00.

About Cambrex

Cambrex Corporation, a life sciences company, provides various products and services for the development and commercialization of new and generic therapeutics worldwide. Its products comprise active pharmaceutical ingredients and pharmaceutical intermediates that are used in the production of prescription and over-the-counter drug products, as well as finished dosage forms.

Featured Article: What Are Cryptocurrencies?

Receive News & Ratings for Cambrex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cambrex and related companies with MarketBeat.com's FREE daily email newsletter.